Literature DB >> 25118162

Axillary burden of disease following false-negative preoperative axillary evaluation.

Chantal Reyna1, Marie C Lee2, Anne Frelick3, Nazanin Khakpour1, Christine Laronga1, John V Kiluk1.   

Abstract

BACKGROUND: Preoperative axillary ultrasound (AUS) and fine-needle aspiration (FNA) are sensitive and specific for breast cancer nodal metastases. We hypothesize that false-negative result predicts minimal axillary disease (≤2 +nodes).
METHODS: A retrospective review of breast cancer patients receiving AUS identified T1/T2 tumors and positive sentinel node with axillary dissection. Chi-square analysis was performed using Fisher's exact test.
RESULTS: Of 903 AUS cases, 384 had T1/T2 tumors. False-negative rate of AUS ± FNA was 48% and 45%, respectively. Of 384 cases, 73 were sentinel node positive and had axillary dissection; 55 (75.3%) were invasive ductal carcinoma (IDC). Negative predictive value for greater than or equal to 2 nodes was 71% in IDC versus 44% for in non-IDC patients. Sixteen (29.0%) IDC patients had greater than or equal to 3 positive nodes versus 10 (55.5%) non-IDC (P = .05) patients.
CONCLUSION: The high negative predictive value for AUS with FNA for IDC suggests that the AUS plus FNA interpretation may be better limited to the ipsilateral nodes of IDC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Axillary ultrasound; False negative; Pathologic burden

Mesh:

Year:  2014        PMID: 25118162     DOI: 10.1016/j.amjsurg.2014.05.015

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Implications of abnormal preoperative axillary imaging in the post Z011 era.

Authors:  Matthew Selleck; Maheswari Senthil
Journal:  Gland Surg       Date:  2016-06

2.  The impact of preoperative axillary ultrasonography in T1 breast tumours.

Authors:  Javier del Riego; María Jesús Diaz-Ruiz; Milagros Teixidó; Judit Ribé; Mariona Vilagran; Lydia Canales; Melcior Sentís
Journal:  Eur Radiol       Date:  2015-07-12       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.